AbbVie agreed to pay $90 million upfront under a global agreement to develop Teneobio's experimental BCMA-targeting immunotherapeutic TNB-383B for patients with multiple myeloma, the companies reported Monday. The bispecific antibody, which is expected to enter clinical development in the first half of this year, uses Teneobio's anti-CD3 platform to simultaneously target BCMA and CD3.
Under the deal, Teneobio's affiliate TeneoOne will continue developing TNB-383B through Phase I studies, with AbbVie holding an exclusive right to acquire TeneoOne and lead subsequent global development and commercialisation. The companies noted that if AbbVie exercises its right, the former stockholders of TeneoOne will also be eligible for regulatory and commercial sales milestones.
The news comes after AbbVie signed a deal last month with Tizona Therapeutics to jointly develop and commercialise CD39-targeted therapeutics for various cancer indications. Previously, the drugmaker acquired exclusive global rights to Lupin's investigational MALT1 inhibitor programme, which it plans to develop for a number of haematological cancers, in a deal potentially worth as much as $947 million.
For related analysis, see ViewPoints: AbbVie enters bi-specific BCMA race, and ViewPoints: bluebird, Celgene provide timely reminder of who's leading the BCMA race.
To read more Top Story articles, click here.